Summary
Assessments of the direct and indirect costs of cancer treatment have demonstrated the extreme complexity of these costs. Expenditure on cancer treatment is high, often reaching 3 to 6% of the gross national product in industrialised countries. In this article, we propose that the health outcomes associated with this high expenditure should be analysed in relation to concepts such as total cytoreduction (leading to disease-free survival and cure) and cytostabilisation with acceptable quality of life (in incurable cancer patients). Outcomes appear to be more variable among incurable compared with curable patients, so that cure and survival (which apply to only about 50% of all patients) are not the sole outcome parameters. For the 50% of patients in industrialised countries in whom cure is not possible, outcomes (in the form of cytostabilisation and an ongoing obligation to seek curative cytoreduction) will require further pharmacoeconomic assessment.
Similar content being viewed by others
References
Skipper HE, Schabel FM, Wilcox WS. Experimental evaluation of potential anticancer agents XIII, on the criteria and kinetics associated with curability of experimental leukaemia. Cancer Chemother Rep 1964; 35: 1–24
Eberlein TJ, Wilson RE. Principles of surgical oncology. In: Holleb AI, Fink DJ, Murphy GP, editors. Clinical oncology. Atlanta: American Cancer Society, 1991: 25–34
American Cancer Society. Cancer facts and figures 1990. Atlanta: American Cancer Society, 1991
WHO. WHO health statistics annual 1990: age-standardized death rates. Geneva: WHO, 1991: 378–84
National Center for Health Statistics. Health United States 1991. Hyattsville (MD): Public Health Service, 1992 (OHHS publication no. PHS 92–1232)
Jönsson B, Karlsson G. Economic evaluation of cancer treatments. In: Williams CJ, editor. Introducing new treatments for cancer: practical, ethical and legal problems. New York: John Wiley & Son, 1992: 237–65
Schipper H, Goh CR, Wang TUL. Rethinking cancer: should we control rather than kill? Part I. Can J Oncol 1993; 3: 207–16
Schipper H, Goh CR, Wang TUL. Rethinking cancer: should we control rather than kill? Part 2. Can J Oncol 1993; 4: 220–4
Astrow AB. Rethinking cancer. Lancet 1994; 343: 494–5
Harker WG, Ward JH, Steward JR. Principles of therapy and effects of specific drugs in the treatment of neoplastic diseases of the haematopoietic system. In: Lee GR, Bithell TC, Foerster J, et al., editors. Wintrobe’s clinical haematology. Philadelphia: Lea & Fibiger, 1993: 1843–72
Goldhirsch A, Gelber RD, Simon R, et al. Costs and benefits of adjuvant therapy in breast cancer, a quality-adjusted survival analysis. J Clin Oncol 1989; 7: 36–44
Kritz A, Crown JP, Motzer RJ, et al. Beneficial impact of peripheral blood progenitor cells in patients with metastatic breast cancer treatment with high-dose chemotherapy plus granulocyte-macrophage colony stimulating factor. Cancer 1993; 71: 2515–21
Richtsmeier WJ. Biological modifiers and chemoprevention of cancer of the oral cavity. N Engl J Med 1993; 328: 58–9
Vernon SW, Heckel V, Jackson GL. Medical outcomes of care for breast cancer among health maintenance organization and fee-for-service patients. Clin Cancer Res 1995 Feb; 1: 179–84
Pettengell R, Gurney H, Radford JA, et al. Granulocyte-colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin’s lymphoma: a randomized controlled trial. Blood 1992; 80: 1430–6
Antman K, Ayash L, Elias A, et al. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol 1992; 10: 102–10
Peters WP, Ross M, Vredenbourgh JJ, et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993; 11: 1132–43
de Graaf H, Willemse PHB, de Vries EGH, et al. Intensive chemotherapy with autologous bone marrow transfusion as primary treatment in women with breast cancer and more than five involved axillary lymph nodes. Eur J Cancer 1994; 30: 150–3
Torrance GW. Utility approach to measuring health-related quality of life. J Chron Dis 1987; 40: 593–600
Loomers G, MacKenzie L. The use of QALYs in health care decision making. Soc Sci Med 1989; 28: 299–308
Mehrez A, Gafni A. Quality-adjusted life years, utility theory, and healthy-years equivalents. Med Decis Making 1989; 9: 142–9
Ganz PA. Quality of life measures in cancer chemotherapy. PharmacoEconomics 1994; 5 (5): 376–88
Gotay CC, Korn EC, McCabe MS, et al. Quality-of-life assessments in cancer treatment protocols: research issues in protocol development. J Natl Cancer Inst 1992; 84: 575–8
Robinson R. Cost and cost-minimization analysis. BMJ 1993; 307: 726–8
Robinson R. Cost-utility analysis. BMJ 1993; 307: 859–62
Hancock BW, Ahmedzai S, Clark D. Palliative care of patients with terminal cancer. Curr Opin Oncol 1993; 5: 655–60
Kaasa S. Measurements of quality of life in clinical trials. Oncology 1992; 49: 288–94
MacDonald N. The interface between oncology and palliative medicine. In: Doyle D, Hanks G, MacDonald N, editors. Oxford textbook of palliative medicine. Oxford: Oxford Medical Publications, 1993: 11–7
Wilson JB, Cleary PD. Linking clinical variables with health-related quality of life: a conceptual model of patient outcome. JAMA 1995; 273: 59–65
Shulman SR, Gouveia W. Therapeutic substitution: an option for cost-effective prescribing? PharmacoEconomics 1993; 3 (4): 257–9
Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press, 1987
Sagmeister M, Gessner U, Horisberger B. Assessment of the cost of a febrile neutropenic event in chemotherapy as a basis for socio-economic evaluation of a new cancer treatment. Int J Health Sci 1991; 2: 1–10
Emanuel EJ, Emanuel LL. The economics of dying: the illusion of cost saving at the end of life. N Engl J Med 1994; 330: 540–4
Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991; 325: 164–70
Carlsson P, Hjertberg H, Jönsson B, et al. The costs of prostatic cancer in a defined population. Scand J Urol Nephrol 1989; 23: 93–6
Tattersall MHN, Friedlander ML. Cost considerations in cancer chemotherapy. Aust Health Rev 1982; 5: 21–4
Clinton B. The Clinton health care plan. N Engl J Med 1992; 327: 804–7
Fries JF, Koop CE, Beadier CE, et al. Reducing health care costs by reducing the need and demand for medical services. N Engl J Med 1993; 329: 321–5
Moinpoure CM, Frigl P, Metch B, et al. Quality of life endpoints in cancer clinical trials, review and recommendations. J Natl Cancer Inst 1989; 81: 485–95
Mayfield SG, Gantz PA, Moinpoure CM, et al. Report from a National Cancer Institute (USA) workshop on quality of life assessment in cancer clinical trials. Qual Life Res 1992; 1: 203–10
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jønsson, V., Clausen, S.R. & Hansen, M.M. Pharmacoeconomic Aspects in the Treatment of Curable and Incurable Cancer. Pharmacoeconomics 8, 275–281 (1995). https://doi.org/10.2165/00019053-199508040-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-199508040-00002